Professor of Oncology, Johns Hopkins University School of Medicine; Co-Director, Skip Viragh Center for Pancreas Cancer, Ian T. MacMillan Professorship in Clinical Pancreatic Cancer Research
Oncology
Dr. Daniel A. Laheru, MD
|
|
Give Review
Daniel Laheru practices Oncology. He researched medicine at Baylor College of Medicine. He over the years received 5 awards: "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer", "Top Doctors:Baltimore Area" and "Top Doctors:Washington-Baltimore". Daniel Laheru is a published doctor and has 34 publications published. The lastest was: 'A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET).' Daniel Laheru accepts Medicare payments and is listed with Medicare.gov.
Publications
- Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
- Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.
- A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine Tumors (PanNET).
- Resected pancreatic Ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns.
- Correlation of clinical stage and performance status with quality of life in patients seen in a pancreas multidisciplinary clinic.
- The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
- What is the Significance of Indeterminate Pulmonary Nodules in Patients Undergoing Resection for Pancreatic AdenoCarcinoma?
- Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenoCarcinoma.
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors.
- A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
- The prognostic value of stroma in pancreatic Cancer in patients receiving adjuvant therapy.
- Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereot...
- Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenoCarcinoma after first-line gemcitabine therapy (PCRT O4-001).
- A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte-Macrophage Colony Stimulating Factor-Producing Bystander Cell...
- A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenoCarcinoma.
- dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic Cancer: A dual-institutional follow-up with the RTOG 9704 trial.
- Detection of circulating tumor DNA in early- and late-stage human malignancies.
- Baseline hemoglobin-a1c impacts clinical outcomes in patients with pancreatic Cancer.
- Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer.
- Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic Cancer after multimodality therapy: exp...
- Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenoCarcinoma: a new approach to adjuvant radiation field design.
- Correlation of smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for Pancreatic adenoca...
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine.
- Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic Cancer.
- Low Total Lymphocyte Count Is Associated with Poor Survival in Patients with Resected Pancreatic AdenoCarcinoma Receiving a GM-CSF Secreting Pancreatic Tumor Vaccine.
- A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic Cancer.
- Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic Cancer.
- Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal Cancer.
- Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results.
- Treating patients with colon Cancer liver metastasis: a nationwide analysis of therapeutic decision making.
- DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic Cancer.
- Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid Tumors.
- A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancre...
Schools
Baylor College Of Medicine
University Utah Hospital and Clins
Johns Hopkins Oncol Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
Education
-
Johns Hopkins University -
University of Utah -
Baylor College of Medicine
Hospital
-
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center
Drug Facts
| NPI NUMBER | 1497796510 | |
| NPPES Provider LastName | LAHERU | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 283.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 4.59 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497796510 |
| Last Name Of The Provider | LAHERU |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
|
Dr. Jean A. Yared, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yvette L. Kasamon, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mian K. Khalid, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stuart A. Grossman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin J. Cullen, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Arlene A. Forastiere, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard J. Jones, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Tanya M. Prowell, MD
This Doctor is OpenDoctor Recommended.
|